{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:19:44Z","timestamp":1790716784166,"version":"4.1.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bill and Melinda Gates Foundation (US)","award":["OPP1092074"],"award-info":[{"award-number":["OPP1092074"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1146996"],"award-info":[{"award-number":["OPP1146996"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1146996"],"award-info":[{"award-number":["OPP1146996"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1146996"],"award-info":[{"award-number":["OPP1146996"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI136578"],"award-info":[{"award-number":["K23AI136578"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0219142","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T17:29:45Z","timestamp":1565285385000},"page":"e0219142","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":84,"title":["Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6987-1478","authenticated-orcid":true,"given":"Yehuda Z.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Millard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggi","family":"Witmer-Pack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeka","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Unson-O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshni","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Shimeliovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C. C.","family":"Lorenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-9370","authenticated-orcid":true,"given":"Stephen R.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsey","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan C.","family":"deCamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel C.","family":"Nussenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Caskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"issue":"27","key":"ref1","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"MC Thigpen","year":"2012","journal-title":"N Engl J Med"},{"issue":"10013","key":"ref4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"S McCormack","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"JM Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"L Van Damme","year":"2012","journal-title":"N Engl J Med"},{"issue":"3 Suppl 2","key":"ref7","doi-asserted-by":"crossref","first-page":"19146","DOI":"10.7448\/IAS.17.3.19146","article-title":"Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa","volume":"17","author":"A van der Straten","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/QAD.0000000000001859","article-title":"Preference for injectable over oral HIV pre-exposure prophylaxis in public-sector primary-care clinics in Swaziland","volume":"32","author":"MJ Siedner","year":"2018","journal-title":"AIDS"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/COH.0000000000000475","article-title":"Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection","volume":"13","author":"YZ Cohen","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"issue":"47","key":"ref10","doi-asserted-by":"crossref","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"H Mouquet","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6049","key":"ref11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"JF Scheid","year":"2011","journal-title":"Science"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/JVI.03136-14","article-title":"Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes","volume":"89","author":"R Kong","year":"2015","journal-title":"J Virol"},{"issue":"7427","key":"ref13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"F Klein","year":"2012","journal-title":"Nature"},{"issue":"7475","key":"ref14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"M Shingai","year":"2013","journal-title":"Nature"},{"issue":"41","key":"ref15","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1315295110","article-title":"HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice","volume":"110","author":"JA Horwitz","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7557","key":"ref16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"M Caskey","year":"2015","journal-title":"Nature"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10\u20131074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"M Caskey","year":"2017","journal-title":"Nat Med"},{"key":"ref18","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","author":"Y Bar-On","year":"2018","journal-title":"Nat Med"},{"issue":"7724","key":"ref19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"P Mendoza","year":"2018","journal-title":"Nature"},{"issue":"7601","key":"ref20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature17677","article-title":"A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges","volume":"533","author":"R Gautam","year":"2016","journal-title":"Nature"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","article-title":"A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection","volume":"24","author":"R Gautam","year":"2018","journal-title":"Nat Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/19420862.2017.1311435","article-title":"Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults","volume":"9","author":"Y Huang","year":"2017","journal-title":"MAbs"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.4161\/mabs.29095","article-title":"A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design","volume":"6","author":"JP Davda","year":"2014","journal-title":"MAbs"},{"issue":"Suppl 1","key":"ref25","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/QAI.0000000000001316","article-title":"Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation","volume":"75","author":"Q Abdool Karim","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref26","article-title":"Combination therapy with anti-HIV-1 antibodies 3BNC117 and 10\u20131074 maintains viral suppression during treatment interruption","author":"P Mendoza","journal-title":"Nature"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"MR Gaudinski","year":"2018","journal-title":"PLoS Med"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"e1002435","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial","volume":"14","author":"KH Mayer","year":"2017","journal-title":"PLoS Med"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"J Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1084\/jem.20132494","article-title":"Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques","volume":"211","author":"M Shingai","year":"2014","journal-title":"J Exp Med"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"e4505","DOI":"10.1371\/journal.pone.0004505","article-title":"International network for comparison of HIV neutralization assays: the NeutNet report","volume":"4","author":"EM Fenyo","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"e36438","DOI":"10.1371\/journal.pone.0036438","article-title":"International network for comparison of HIV neutralization assays: the NeutNet report II","volume":"7","author":"L Heyndrickx","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.virol.2012.02.001","article-title":"The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant","volume":"427","author":"NM Provine","year":"2012","journal-title":"Virology"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01883-17","article-title":"Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells","volume":"92","author":"YZ Cohen","year":"2018","journal-title":"J Virol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0219142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T20:49:07Z","timestamp":1721594947000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0219142"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0219142","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,8]]}}}